Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Oct 7;2009(4):CD007339.
doi: 10.1002/14651858.CD007339.pub2.

Pentoxifylline for alcoholic hepatitis

Kate Whitfield  1 , Andrea Rambaldi, Jørn Wetterslev, Christian Gluud
Affiliations
Meta-Analysis

Pentoxifylline for alcoholic hepatitis

Kate Whitfield et al. Cochrane Database Syst Rev. .

Abstract

Background: Alcoholic hepatitis is a life-threatening disease, with an average mortality of approximately 40%. There is no widely accepted, effective treatment for alcoholic hepatitis. Pentoxifylline is used to treat alcoholic hepatitis, but there has been no systematic review to assess its effects.

Objectives: To assess the benefits and harms of pentoxifylline in alcoholic hepatitis.

Search strategy: The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, LILACS, clinicaltrials.gov, and full text searches were conducted until August 2009. Manufacturers and authors were contacted.

Selection criteria: All randomised clinical trials of pentoxifylline in participants with alcoholic hepatitis compared to control were selected for inclusion.

Data collection and analysis: Two authors extracted data and evaluated the risk of bias. RevMan Analysis was used for statistical analysis of dichotomous data with risk ratio (RR) and of continuous data with mean difference (MD), both with 95% confidence intervals (CI). Trial sequential analysis (TSA) was also used for statistical analysis of dichotomous and continuous data in order to control for random error. Where data were only available from one trial, we used Fisher's exact test or Student's t-test.

Main results: Five trials, with a total of 336 randomised participants, were included. A total of 105 participants (31%) died. Of the five included trials, four (80%) had a high risk of bias. Meta-analysis using all five trials showed that pentoxifylline reduced mortality compared with control (RR 0.64; 95% CI 0.46 to 0.89). However, this result was not supported by trial sequential analysis, which adjusts for multiple testing on accumulating data. Furthermore, four of the five trials were judged to have a high risk of bias, thus risking an overestimated intervention effect. Meta-analysis showed that pentoxifylline reduced the hepatic-related mortality due to hepatorenal syndrome (RR 0.40; 95% CI 0.22 to 0.71), but trial sequential analysis did not support this result. Data from one trial suggests that pentoxifylline may increase the occurrence of serious and non-serious adverse events compared to control.

Authors' conclusions: The current available data may indicate a possible positive intervention effect of pentoxifylline on all-cause mortality and mortality due to hepatorenal syndrome, and conversely, an increase in serious and non-serious adverse events. However, the evidence is not firm; no conclusions can be drawn regarding whether pentoxifylline has a positive, negative, or neutral effect on participants with alcoholic hepatitis.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Trial sequential analysis of the cumulative meta‐analysis of the effect of pentoxifylline on all‐cause mortality in participants with alcoholic hepatitis. The required information size of 1169 is calculated based on an a priori intervention effect of 20% (APHIS), a risk of type 1 error of 5%, and a power of 80%. The event rate in the control group is 39%, which is based on a meta‐analytic estimate of the control event rate of all the included trials. Although the cumulated z‐curve (blue curve) crosses the traditional boundary of 5% significance (horizontal red line), it does not cross the trial sequential monitoring boundary (red curve), implying that there is no firm evidence for an effect of 20% risk ratio reduction (RRR) when the cumulative meta‐analysis is adjusted for multiple testing on accumulating data.
4
4
Trial sequential analysis of the cumulative meta‐analysis of the effect of pentoxifylline on hepatic‐related mortality in participants with alcoholic hepatitis. The required information size of 1636 is calculated based on an a priori intervention effect of 20% (APHIS), a risk of type 1 error of 5% and a power of 80%. The event rate in the control group is 38%, which is based on a meta‐analytic estimate of the control event rate of all the included trials. Although the cumulated z‐curve (blue curve) crosses the traditional boundary of 5% significance (horizontal red line), it does not cross the trial sequential monitoring boundary (red curve), implying that there is no firm evidence for an effect of 20% risk ratio reduction (RRR) when the cumulative meta‐analysis is adjusted for multiple testing on accumulating data.
5
5
Trial sequential analysis of the cumulative meta‐analysis of the effect of pentoxifylline on serum creatinine in participants with alcoholic hepatitis. The required information size of 252 is calculated based on an intervention effect of 0.25 (mg/dl) (APHIS), a risk of type 1 error of 5% and a power of 80%. The cumulated z‐curve (blue curve) crosses the trial sequential monitoring boundary implying that there is firm evidence for a beneficial effect of 0.25 (mg/dl) decrease in serum creatinine when the cumulative meta‐analysis is adjusted for multiple testing on accumulating data.
6
6
Trial sequential analysis of the cumulative meta‐analysis of the effect of pentoxifylline on serum bilirubin in participants with alcoholic hepatitis. The trial sequential monitoring boundary is not calculated because the actual information size is less than 1% of the information size required. This is calculated based on an intervention effect of 1.00 (mg/dl) suggested by the one trial with low risk of bias.
7
7
Trial sequential analysis of the cumulative meta‐analysis of the effect of pentoxifylline on levels of TNF in participants with alcoholic hepatitis. The required information size of 318 is calculated based on an intervention effect of 4.00 pg/ml, suggested by the one trial with low risk of bias (LBHIS) (Akriviadis 2000), a risk of type 1 error of 5% and a power of 80%. The cumulated z‐curve (blue curve) does not cross the trial sequential monitoring boundary implying that there is no firm evidence for a potentially harmful effect of 4.00 pg/ml when the cumulative meta‐analysis is adjusted for multiple testing on accumulating data.
1.1
1.1. Analysis
Comparison 1 All‐cause mortality, pentoxifylline versus control, Outcome 1 Mortality using the fixed effect model.
1.2
1.2. Analysis
Comparison 1 All‐cause mortality, pentoxifylline versus control, Outcome 2 Mortality using the random effects model.
1.3
1.3. Analysis
Comparison 1 All‐cause mortality, pentoxifylline versus control, Outcome 3 Mortality according to risk of bias.
2.1
2.1. Analysis
Comparison 2 Hepatic‐related mortality, Outcome 1 Hepatic‐related mortality using fixed‐effect model.
2.2
2.2. Analysis
Comparison 2 Hepatic‐related mortality, Outcome 2 Hepatic‐related mortality using the random‐effects model.
3.1
3.1. Analysis
Comparison 3 Sensitivity analysis, all‐cause mortality, Outcome 1 Mortality.
4.1
4.1. Analysis
Comparison 4 Hepatic‐related morbidity, pentoxifylline versus control, Outcome 1 Variceal bleeding.
5.1
5.1. Analysis
Comparison 5 Biochemical parameters, pentoxifylline versus control, Outcome 1 Serum creatinine.
5.2
5.2. Analysis
Comparison 5 Biochemical parameters, pentoxifylline versus control, Outcome 2 Serum bilirubin.
6.1
6.1. Analysis
Comparison 6 Post‐hoc outcome measures, TNF levels, Outcome 1 Tumour necrosis factor.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD007339

References

References to studies included in this review

Akriviadis 2000 {published data only}
    1. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology 1997;26(4 (Pt 2)):250A. - PubMed
    1. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology 2000;119(6):1637‐48. - PubMed
    1. Karnam US, Reddy KR. A toast to pentoxifylline. The American Journal of Gastroenterology 2001;96(5):1635‐7. - PubMed
Lebrec 2007 {published data only}
    1. Lebrec D, Thabut D, Oberti F, Perarnau J‐M, Condat B, Barraud H, et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo‐controlled, double‐blind trial. Hepatology 2007;46(4 Suppl 1):249A.
McHutchison 1991 {published data only}
    1. McHutchison JG, Runyon BA, Draguesku JO, Comineelli F, Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991;14(4 (Pt 2)):96A.
Paladugu 2006 {published data only}
    1. Paladugu H, Sawant P, Dalvi L, Kudalkar J. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology 2006;21:A459.
Sidhu 2006 {published data only}
    1. Sidhu S, Singla M, Bhatia KL. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology 2006;44(4 (Suppl 1)):373A‐374A.

References to studies excluded from this review

Austin 2004 {published data only}
    1. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Alimentary Pharmacology & Therapeutics 2004;19(1):79‐88. - PubMed
Cholongitas 2001 {published data only}
    1. Cholongitas E, Papatheodoridis GV. Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Annals of Gastroenterology 2001;14(4):333‐5. - PubMed
Fernández‐Rodríguez 2008 {published data only}
    1. Fernández‐Rodríguez CM, Lledó JL, López‐Serrano P, Gutiérrez ML, Alonso S, Pérez‐Fernández MT, et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis: a randomized double‐blind placebo‐controlled trial. Revista Española de Enfermedades Digestivas 2008;100(8):481‐9. - PubMed
Lee 2006 {published data only}
    1. Lee YM, Sutedja D, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled double blind study of pentoxifylline in patients with non alcoholic steatohepatitis (NASH). Hepatology 2006;44(4 (Suppl 1)):654A. - PMC - PubMed
Louvet 2008 {published data only}
    1. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non‐responders to corticosteroids. Journal of Hepatology 2008;48:465‐70. - PubMed
    1. Louvet A, Diaz E, Texier F, Coevoet H, Dharancy S, Plane C, et al. Evaluation of pentoxifylline in patients with severe alcoholic hepatitis non‐responders to corticosteriods: a pilot controlled study. Hepatology 2005;42(4 (Suppl 1)):754A. - PubMed
Verma 2006 {published data only}
    1. Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Digestive Diseases and Sciences 2006;51(9):1637‐43. - PubMed
Watson 2008 {published data only}
    1. Watson E, Lafferty H, Forrest EH. When corticosteroids fail: rescue treatment with pentoxifylline for alcoholic hepatitis. Journal of Hepatology 2008;48(S2):S366.

References to studies awaiting assessment

NCT00205049 {published data only}
    1. Pentoxifylline for acute alcoholic hepatitis. http://ClinicalTrials.gov/show/NCT00205049 (accessed 14 August 2009).

References to ongoing studies

NCT00388323 {published data only}
    1. Adipose tissue involvement in alcohol‐induced liver inflammation in human: study of pro‐ and anti‐inflammatory cytokines and adipokines. http://ClincalTrials.gov/show/NCT00388323.

Additional references

Akriviadis 2000
    1. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology 2000;199:1637‐48. - PubMed
Altman 2003
    1. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ (Clinical Research Ed) 2003;326:219. - PMC - PubMed
Begg 1994
    1. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088‐101. - PubMed
Brok 2008
    1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. - PubMed
Brok 2008a
    1. Brok, J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses maybe inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data inapparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. - PubMed
Ceccanti 2006
    1. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. Acute alcoholic hepatitis. Journal of Clinical Gastroenterology 2006;40:833‐41. - PubMed
Christensen 1995
    1. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta‐analysis adjusting for confounding variables. Gut 1995;37(1):113‐8. - PMC - PubMed
DeMets 1987
    1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997;315:629‐34. - PMC - PubMed
Fisher 1922
    1. Fisher RA. On the interpretation of χ2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society 1922;85(1):87‐94.
Gluud 2001
    1. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. FALK Symposium 121. Steatohepatitis (NASH and ASH). 2001; Vol. 121:400.
Gluud 2009
    1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 3. Art. No.: LIVER.
Hardison 1966
    1. Hardison WG, Lee FI. Prognosis in acute liver disease of alcoholic patients. New England Journal of Medicine 1966;275:61‐6. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
ICH‐GCP 1996
    1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice. E6 (R1). ICH Harmonised Tripartite Guideline 1996.
Imperiale 1990
    1. Imperiale F, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis?. Annals of Internal Medicine 1990;113:299‐307. - PubMed
Kjaergard 2001
    1. Kjaerdard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135:982‐9. - PubMed
Lebrec 2007
    1. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo‐controlled, double‐blind trial. Hepatology 2007;46(4 (Suppl 1)):249A‐250A.
Levistsky 2004
    1. Levistsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Seminars in Liver Disease 2004;24(3):233‐46. - PubMed
Lucey 2009
    1. Lucey MR, Mathurin P, Morgan TRM. Alcholic hepatitis. The New England Journal of Meidicine 2009;360:2758‐69. - PubMed
Maddrey 1978
    1. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193‐9. - PubMed
Madhotra 2003
    1. Madhotra R, Gilmore IT. Recent developments in the treatment of alcoholic hepatitis. Oxford Journal of Medicine 2003;96:391‐400. - PubMed
McClain 1989
    1. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349‐51. - PubMed
McCullough 1998
    1. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. The American Journal of Gastroenterology 1998;93(11):2022‐36. - PubMed
McHutchison 1991
    1. McHutchison JG, Runyon BA, Draguesku JO, Cominelli F, Person JL, Castracance J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991;14(4 Pt 2):96A.
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. The Lancet 1998;352:609‐13. - PubMed
Patient 2008
    1. Patient.uk. Pentoxifylline. http://www.patient.co.uk/showdoc/30003859/ (Accessed 30 January 2009).
Poynard 1991
    1. Poynard T, Ramond MJ, Reuff B, Mathurin P, Theodore C, et al. Corticosteroid therapy reduces mortality from alcoholic hepatitis in patients without encephalopathy. A meta‐analysis of randomized trials (RCTs) including French trials. Hepatology 1991;14:234A.
Rambaldi 2009
    1. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Glucocorticosteroids for alcoholic hepatitis. Cochrane Database of Systematic Reviews Under preparation. [DOI: 10.1002/14651858.CD001511] - DOI - PubMed
RevMan 2008 [Computer program]
    1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Rongey 2006
    1. Rongey C, Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World Journal of Gastroenterology 2006;12:6909‐21. - PMC - PubMed
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed
Rücker 2008
    1. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27(5):746‐63. - PubMed
Schulz 1995
    1. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12. - PubMed
Sidhu 2006
    1. Sidhu S, Singla M, Bhatia KL. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology 2006;44 Suppl 4(1):373A.
Strieter 1988
    1. Strieter R, Remick D, Ward P, Spengler RN, Lynch JP 3rd, Larrick J. Cellular and molecular regulation of tumor necrosis factor‐alpha production by pentoxifylline. Biochemical and biophysical research communications 1988;155:1230‐6. - PubMed
Student 1908
    1. Student. The probable error of a mean. Biometrika 1908;6(1):1–25.
Thorlund 2008
    1. Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38:276–86. - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5. - PMC - PubMed

MeSH terms